Hanbang Biotech: Stock price has been fluctuating abnormally, with expected losses and incomplete reduction plans.

Hanbang Biological announced that from February 24th to 26th, 2026, the company's stock price has shown abnormal fluctuations, with the closing price deviating by more than 20% for three consecutive trading days. After a self-examination, the company confirmed that its production and operation are normal, and there are no undisclosed major issues that should be disclosed. The finance department's preliminary calculations show that the net profit attributable to the shareholders of the listed company for the year 2025 is expected to be a loss of 4.7 to 5.7 billion yuan, with a non-GAAP net profit expected to be a loss of 4.6 to 5.6 billion yuan. In addition, the company plans to reduce its previously repurchased shares by no more than 177 million shares from March 2nd to September 1st, 2026, and this plan has not been fully implemented yet.